IDARUBICIN IN THE INITIAL TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - THE EFFECT OF DRUG SCHEDULE ON OUTCOME

被引：16

作者：

BASSAN, R

BATTISTA, R

CORNEO, G

ROSSI, G

LAMBERTENGHIDELILIERS, G

VIERO, P

RAMBALDI, A

DEMILIO, A

NEONATO, MG

POGLIANI, E

ORIANI, A

IZZI, T

DINI, E

BARBUI, T

机构：

[1] Divisione di Ematologia Ospedali Riuniti, Bergamo

[2] Ospedale Generale San Bortolo, Vicenza

[3] Ospedale San Gerardo, Monza

[4] Spedali Civili, Brescia

[5] Istituto di Scienze Mediche, Università di Milano, Milano

[6] Istituto Ricerche Farmacologiche Mario Negri, Bergamo

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 1-2期

关键词：

IDARUBICIN; ALL; REMISSION INDUCTION;

D O I：

10.3109/10428199309054736

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifty two adults (aged 15 to 66 years) with newly diagnosed acute lymphoblastic leukemia (ALL, n = 47) or lymphoid blast phase chronic myelogenous leukemia (Ly-CML, n = 5) were managed with three distinct protocols containing idarubicin at a cumulative dose of 36, 20, and 10 mg/m2, respectively, plus vincristine, L-asparaginase, and prednisolone (IVAP-1, -2, -3). IVAP-1 was highly toxic and gave a low complete remission (CR) rate (7/17, 41%). Nine patients died of complications while severely neutropenic, and one had resistant disease. In contrast, 24 of 28 patients subsequently treated with IVAP-2 achieved a CR (86%, p 0.005), the rate of both hematological and extrahematological toxicity being significantly reduced compared with IVAP-1 (p < 0.05). With IVAP-3, 6/7 patients aged >60 years achieved CR. IVAP-2 with total idarubicin 20 mg/m2 is a very effective and well tolerated regimen for the initial treatment of adults with ALL.

引用

页码：105 / 110

页数：6

共 24 条

[1] Berman E., Heller G., Santorsa P.A., McKenzie S., Gee T., Kenipin S., Gulati S., Andreef M., Kolitz I., Gabri-Lovo J., Reich L., Mayer K., Keefe D., Trainor K., Schinger A., Penenberg D., Raymond V., O'Reilly R., Jhanwar S., Young C., Clarkson B., Results of a randomized trial comparing idarubicin and cytohine arabi-noside with daunorubicin and cytosine ardbinoside in adult patients with newly diagnosed acute myelogenous leukemia, Blood, 77, pp. 1666-1674, (1991)
[2] Wiernik P.H., Banks P.L.C., Case D.C., Arlin Z.A., Periman P.O., Todd M.B., Ritch P.S., Enck R.E., Weitberg A.B., Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia, Blood, 79, pp. 313-319, (1992)
[3] Petti M.C., Mandelli F., Idarubicin in acute leu-kemias: experience of the Italian cooperative group GI-MEMA, Semin. Oncol., 16, pp. 10-15, (1989)
[4] Gottlicb A.J., Weinberg W., Ellison R.R., Henderson E.S., Terebelo H., Rafla S., Cuttner J., Silver R.T., Carey R.W., Levy R.N., Hutchinson J.L., Raich P., Cooper M.R., Wiernik P., Anderson J.R., Holland J.F., Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B, Blood, 64, pp. 267-274, (1984)
[5] Linker C.A., Levitt L.J., O'Donnell M., Ries C.A., Link M.P., Forman S.J., Ries C.A., Treatment of adult acute Iymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report, Blood., 78, pp. 2814-2822, (1991)
[6] Radlord J.E., Burns C.P., Jones M.P., Gingrich R.G., Kemp J.D., Edwards R.W., McFadden D.B., Dick F.R., Wen B.-C., Adult acute lymphoblastic leukemia: results of the lowa HOP-L protocol, J. Clin. Oncol., 7, pp. 58-66, (1989)
[7] Bassan R., Battista R., D'Emilio A., Viero P., Dragone P., Dini E., Barbui T., Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia, Eur. J. Cancer, 27, pp. 441-447, (1991)
[8] Ellison R.R., Mick R., Cuttner J., Schiffer C.A., Silver R.T., Henderson E.S., Woliver T., Royston I., Davey F.R., Glicksman A.S., Bloomfield C.D., Holland J.F., The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B, J. Clin. Oncol., 9, pp. 2002-2015, (1991)
[9] Bassan R., Rambaldi A., Viero P., Borleri G., Barbui T., Integrated use of morphology, cytochemistry, and iminune marker analysis to identify acute leukaemia subtypes, Haematologica, 74, pp. 487-490, (1989)
[10] Sobol R.E., Mick R., Royston I., Davey F.R., Ellison R.R., Newman R., Cuttner J., Griffin J.D., Collins H., Nelson D.A., Bloomfield C.D., Clinical importance or myeloid antigen expression in adult acute lymphoblastic leukemia, N. Engl. J. Med., 316, pp. 1111-1117, (1987)

← 1 2 3 →